Infantile Spasm Treatment Market, by Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), by Route of Administration (Oral and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

  • Published On : Jan 2019 |
  • Pages : 150 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Infantile Spasm Treatment Market – Rich Product Pipeline for Rare Disease

Infantile spasm treatment play a major role in modern healthcare, as they are used for the treatment of seizures of an epilepsy syndrome in infants usually below 1 year.

The global infantile spasm treatment market size was valued at US$ 111.1 million in 2017 and is expected to exhibit a CAGR of 3.1% over the forecast period (2018 – 2026).

Figure 1. Global Infantile Spasm Treatment Market Value (US$ Mn), by Region, 2017

Infantile Spasm Treatment  | Coherent Market Insights

                                                                  Source: Coherent Market Insights Analysis (2018)

Increasing government initiatives for treatment of rare diseases is expected to propel growth of the infantile spasm treatment market

Infantile spasm, also called as west syndrome, is a rare disorder that affects children below 1 year age. Seizures in children often appear as normal hiccups or body movement, and parents are unaware about the presence of this disease in their kid. Therefore, to tackle this challenge, various governments and organizations are initiating programs to educate people about the disease. The government of China published a comprehensive list of rare diseases in 2018, in order to better identify the patients affected by rare disease and provide treatment for the same. Moreover, such initiatives will help to speed up the drug development process for rare diseases.  

Increasing birth rate could result in high prevalence of infantile spasm, which is expected to drive growth of the infantile spasms treatment market over the forecast period.

However, high cost of treatment, lack of proper diagnosis of infantile spasm, and stringent regulations for drug approval are some of the factors hindering the market growth. For instance, Acthar, which is a corticotropin branded product from Mallinckrodt pharmaceutical, costs around US$ 125,000 per patient, i.e. US$ 28,000 per dose

Figure 2. Global Infantile Spasm Treatment Market Share (%), by Product Type, 2018 and 2026

Infantile Spasm Treatment  | Coherent Market Insights

                                                                Source: Coherent Market Insights Analysis (2018)

Increasing adoption of infantile spasms treatment procedure in North America is expected to bolster the market growth

North America holds dominant position in the global infantile spasm treatment market, owing to high adoption of infantile spasms treatment procedures and large scale research and development activities in this region. For instance, INSYS Therapeutics developed Cannabidiol in October 2012, Oral Solution for infantile spasm, which is under phase III clinical trial. The reoccurrence of infantile spasm is a major factor that boosts the market growth.

Increasing prevalence of central nervous system (CNS) infection can develop infantile spasm which in turn is expected to boost the market growth. In July 2012, the National Center for Biotechnology Information (NCBI) report stated that around 50% of infantile spasm cases in the U.S. have a prenatal cause, including central nervous system infection, intrauterine insults, neurologic disorders such as tuberous sclerosis complex (TSC), and genetic syndrome.

Moreover, approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) that helps in speedy approval by designating the orphan drug status to drugs targeted to benefit patients with rare disease is expected to boost the market growth.

Key Players

Major players operating in the global infantile spasm market include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics, Inc., and Anavex Life Sciences Corp.

Infantile spasm is a rare disorder that appears as seizures in infants below 1 year. Infantile spasm causes series of sudden, jerking movements of legs and arms or fast drop of head. The duration of spasm can last up to couple of seconds. Major drugs used for the treatment of infantile spasm include adrenocorticotropic hormone (ACTH), however, due to its side effects, doctors also prefer anti-seizure drugs such as vigabatrin and other steroid therapies.

Market Dynamics

Increasing prevalence of central nervous system infection, may develop infantile spasm which in turn is expected to boost the infantile spasm treatment market. According to the National Center for Biotechnology Information (NCBI), in January 2018, the prevalence of infantile spasm was 2 to 3.5 infants per 10,000 live births.

Government initiatives for rare disease treatment is expected to boost the market growth. For instance, The American Academy of Pediatrics also works with the Child Neurology Society, Child Neurology Foundation, American College of Emergency Physicians, and other partners to build advocacy, identify awareness gaps, and expand outreach opportunities.

The relapse or reoccurrence of infantile spasm is a major factor driving growth of the infantile spasm treatment market. According to investigators from Okayama University Hospital, Japan, after the treatment of infantile spasm with ACTH therapy for 11 to 37 days, the disease reoccurred in 41% of the people under study.

Moreover, the government of Brazil in year 2017 amended its regulatory rules for approving drugs for rare disease. In December 2017, Brazilian regulatory agency, Agência Nacional de Vigilância Sanitária (ANVISA) published Resolution RDC 205/2017, regulating special procedures for clinical trials, registration, and certification of Good Manufacturing Practices (GMPs) of drugs intended to treat, prevent or diagnose rare diseases such as infantile spasm.

Key features of the study:

  • This report provides in-depth analysis of the infantile spasm treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global infantile spasm treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics, Inc., and Anavex Life Sciences Corp.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global infantile spasm treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the infantile spasm treatment market

Detailed Segmentation:

  • Global Infantile Spasm Treatment Market, By Product Type:
    • Adrenocorticotropic Hormone (ACTH)
    • Vigabatrin
    • Phase III
  • Global Infantile Spasm Treatment Market, By Route of Administration:
    • Oral
    • Parenteral
  • Global Infantile Spasm Treatment Market, By Region:
    • North America
      • By Product Type:
        • Adrenocorticotropic Hormone (ACTH)
        • Vigabatrin
        • Phase III
      • By Route of Administration:
        • Oral
        • Parenteral
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Adrenocorticotropic Hormone (ACTH)
        • Vigabatrin
        • Phase III
      • By Route of Administration:
        • Oral
        • Parenteral
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Adrenocorticotropic Hormone (ACTH)
        • Vigabatrin
        • Phase III
      • By Route of Administration:
        • Oral
        • Parenteral
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Adrenocorticotropic Hormone (ACTH)
        • Vigabatrin
        • Phase III
      • By Route of Administration:
        • Oral
        • Parenteral
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Adrenocorticotropic Hormone (ACTH)
        • Vigabatrin
        • Phase III
      • By Route of Administration:
        • Oral
        • Parenteral
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Adrenocorticotropic Hormone (ACTH)
        • Vigabatrin
        • Phase III
      • By Route of Administration:
        • Oral
        • Parenteral
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • H. Lundbeck A/S*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Mallinckrodt Pharmaceuticals
    • Catalyst Pharmaceuticals
    • GW Pharmaceuticals plc
    • Retrophin, Inc.
    • Valerion Therapeutics
    • Orphelia Pharma SA
    • Insys Therapeutics, Inc.
    • Anavex Life Sciences Corp. 

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Route Of Administration
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Diagnostic Algorithm For Infantile Spasms
    • Treatment Options In Infantile Spasms
    • Relapse In Infantile Spasms
    • Pipeline Analysis
    • Organizations Providing Infantile Spasms Information
    • Challenges Faced By Rare Disease Drug Discovery Programs
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
  4. Global Infantile Spasm Treatment Market, By Product Type, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Adrenocorticotropic Hormone (ACTH)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Vigabatrin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Phase III
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  5. Global Infantile Spasm Treatment Market, By Route of Administration, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Parenteral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  6. Global Infantile Spasm Treatment Market, By Region, 201 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Germany
        • U.K.
        • France        
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      •  H. Lundbeck A/S
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mallinckrodt Pharmaceuticals
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Catalyst Pharmaceuticals
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GW Pharmaceuticals plc
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Retrophin, Inc.
        •  Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      •  Valerion Therapeutics
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Orphelia Pharma SA
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Insys Therapeutics, Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Anavex Life Sciences Corp. 
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 39 market data tables and 29 figures on "Infantile Spasm Treatment Market - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.